Collagens make up the most abundant component of interstitial extracellular matrices and basement membranes. Collagen remodeling is a crucial process in many normal physiological events and in several pathological conditions. Some collagen subtypes contain specific carbohydrate side chains, the function of which is poorly known. The endocytic collagen receptor urokinase plasminogen activator receptor-associated protein (uPARAP)/Endo180 plays an important role in matrix remodeling through its ability to internalize collagen for lysosomal degradation. uPARAP/Endo180 is a member of the mannose receptor protein family. These proteins all include a fibronectin type II domain and a series of C-type lectin-like domains, of which only a minor part possess carbohydrate recognition activity. At least two of the family members, uPARAP/Endo180 and the mannose receptor, interact with collagens. The molecular basis for this interaction is known to involve the fibronectin type II domain but nothing is known about the function of the lectin domains in this respect. In this study, we have investigated a possible role of the single active lectin domain of uPARAP/Endo180 in the interaction with collagens. By expressing truncated recombinant uPARAP/Endo180 proteins and analyzing their interaction with collagens with high and low levels of glycosylation we demonstrated that this lectin domain interacts directly with glycosylated collagens. This interaction is functionally important because it was found to modulate the endocytic efficiency of the receptor toward highly glycosylated collagens such as basement membrane collagen IV. Surprisingly, this property was not shared by the mannose receptor, which internalized glycosylated collagens independently of its lectin function. This role of modulating its uptake efficiency by a specific receptor is a previously unrecognized function of collagen glycosylation.

The breakdown and remodeling of the extracellular matrix (ECM) \(^2\) including the basement membrane are important steps in embryonic growth, tissue rearrangements in the healthy body, and invasive cancer growth (1–3). The ECM is composed of a range of different structural proteins, including collagens, laminins, fibronectin, and proteoglycans. The collagens make up by far the most abundant component. Collagens are trimeric proteins that form unique triple helices and assemble into large supramolecular structures such as fibers and sheets, enabling them to form the barriers and structures of the ECM (4).

Collagens undergo a range of post-translational modifications, including extensive hydroxylation of prolyl and lysyl residues, N- and O-linked glycosylation, and processing of pro-forms \(^5\). The hydroxylation of proline and lysine residues plays a role in triple helix stabilization and cross-linking of collagen molecules and the processing of pro-forms is important for the assembly of collagens into fibrillar structures \(^6\). In contrast, the role of collagen glycosylation is poorly understood. Most is known about the O-linked glycosylation and this type of collagen glycosylation is composed of a single galactose unit or a disaccharide consisting of galactose and glucose attached to hydroxylated lysine residues \(^7\). The level of O-glycosylation varies greatly between different types of collagen and between different tissues. The network-forming collagen type IV of the basement membrane and the fibrillar collagen type V have high levels of glycosylation \(^8–11\), whereas collagen type I in the skin and tendon has very low levels \(^12, 13\). Some studies have demonstrated an importance of glycosylation in collagen function in processes of mouse development, however, the mechanism of action remains unknown \(^14–16\). In particular, it is an open question if collagen glycosylation affects collagen interaction with other proteins and processes like collagen turnover.

Collagen turnover is complex and involves different mechanisms and degradation pathways. The unique structure of collagens makes them resilient to most means of proteolytic attack and only relatively few proteases are known to degrade collagens in their native state. Most of these active collagenases are secreted or membrane-bound members of the matrix metalloproteinase family \(^17, 18\).
However, in addition to extracellular degradation, a pathway for intracellular degradation of collagen has been identified (19). This pathway involves collagen endocytosis mediated by the urokinase plasminogen activator-receptor-associated protein (uPARAP) (20), also designated Endo180 (21). This protein, designated uPARAP in the following, is a member of the mannose receptor family of endocytic receptors (22–24). uPARAP is expressed at sites with ongoing tissue remodeling (25–28) and functions in delivering collagens for intracellular degradation in lysosomes (29–35). In some processes the receptor operates together with extracellular collagen degradation mechanisms and it is effective in internalizing the large cleavage products resulting from initial extracellular collagenase digestion (36–38). The importance of this pathway of collagen turnover in vivo was emphasized in a recent study of a devastating hereditary bone defect in cattle, which turned out to be caused by an inactivating frameshift mutation in the uPARAP encoding gene (39).

The involvement of uPARAP in extracellular matrix remodeling has underscored the importance of understanding the molecular basis of the ligand interactions of the receptor and several studies during the last decade have provided information in this regard. uPARAP consists of a large extracellular part, a transmembrane domain, and a short cytoplasmic domain (Fig. 1A). The extracellular part of uPARAP includes 10 domains as predicted from the amino acid sequence (21, 40). The collagen binding activity of uPARAP has been ascribed to a fibronectin type II (FN-II) domain in the protein structure, whereas the other domains of the receptor have so far been considered devoid of collagen interaction sites (30, 31). Interestingly, the receptor includes eight C-type lectin-like domains (CTLD1–8) but only one of these, CTLD-2, possesses lectin activity (41). This domain includes an essential calcium-binding site and specifically binds a range of monosaccharides, including mannose, glucose, and N-acetylgalactosamine (GlcNAc), in a calcium-dependent reaction (41). However, no biological ligand has so far been associated with the lectin activity of uPARAP.

In the present work, we show that CTLD-2 of uPARAP participates in the binding to specific collagens with a high degree of glycosylation, that CTLD-2 indeed interacts directly with carbohydrate residues on collagens through its lectin function, and that the resulting combined activity of FN-II and CTLD-2 serves to specifically increase the binding of uPARAP to glycosylated collagens. Furthermore, we demonstrate an impact of this lectin activity on the efficiency of uPARAP-dependent collagen internalization in cultured cells. Through this mechanism, the type-specific and dynamic pattern of collagen glycosylation may add to determine the efficiency of collagen turnover through the uPARAP-mediated endocytic degradation route. Surprisingly, we find that this lectin dependence in collagen internalization is limited to uPARAP because the related collagen endocytosis receptor, the mannose receptor (MR) (42, 43), does not depend on lectin activity in enabling the internalization of collagen by macrophages.

**EXPERIMENTAL PROCEDURES**

Reagents and Cultured Cells—The following proteins and other reagents were purchased from commercial sources as indicated: endoglucosidase H (EndoH) from Streptomyces pileatus (New England Biolabs, Ipswich, MA), native, trypsin-resistant collagen type I from rat tail (BD Biosciences), native collagen type IV and V isolated from human placenta, holofermin, and cysteine protease inhibitor E64d (Merck Biosciences, Darmstadt, Germany), mannose-BSA (Dextra Laboratories, Reading, United Kingdom), d-mannose, N-acetyl-d-glucosamine (GlcNAc), α-methyl-d-galactopyranoside (α-Me-Gal), bovine serum albumin (BSA), granulocyte macrophage-colony stimulating factor, and trifluoromethanesulfonic acid (TFMS) deglycosylation kit (Sigma), 125I for protein labeling (PerkinElmer Life Sciences), Oregon Green-conjugated gelatin and Alexa Fluor 488 microscale protein labeling kit (Invitrogen), goat polyclonal antibody against human MR (pAb a-MR) (R&D Systems, Minneapolis, MN), and Cy3-conjugated goat anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA). The monoclonal mouse anti-uPARAP antibodies 5f4 and 2h9 have been described previously (37, 44). The cell surface marker, monoclonal antibody mR3 against murine urokinase receptor was produced as described (45).

Fibroblasts from the skin of newborn homozygous uPARAP-deficient mice and littermate wild type mice were isolated and cultured as described (29). Human osteosarcoma cells (MG63 cell line; ATCC number CRL-1427) were cultured in minimum Eagle’s medium (Invitrogen) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Human macrophages were generated as previously described (43, 46) with minor modifications. In brief, mononuclear cells were isolated from whole blood from normal, healthy volunteers, using density gradient centrifugation (Lymphoprep, Axis Shield, Dundee UK). After this monocytes were isolated using an automated cell isolator (RoboSep) and EasySep Human Buffy Coat CD14 Selection Kit (Stemcell Technologies, Grenoble, France). Following isolation, monocytes were cultured for 8 days in AIM-V medium with l-glutamine, streptomycin, gentamycin, and human serum albumin (Invitrogen) and supplemented with 10% FCS and 5 ng/ml of granulocyte macrophage-colony stimulating factor for differentiation into macrophages. The medium was replenished on days 4 and 7.

Recombinant uPARAP Variants—Three recombinant truncated uPARAP variant proteins designated D1–3, D1–4, and D1–10 were generated (Fig. 1). These proteins comprise the first three N-terminal domains (Gly31–Ala365), the first four N-terminal domains (Gly31–Leu510), and all of the 10 extracellular domains (Gly31–Ser1405) in the human uPARAP sequence, respectively (21, 40). D1–3 and D1–4 were produced in a Pichia pastoris-based expression system (Invitrogen). In brief, the DNA sequences encoding D1–3 and D1–4 were amplified by PCR from a uPARAP expression vector (37) and fused with a sequence encoding a C-terminal His6 tag, a stop codon, and appropriate restriction sites for subsequent cloning into the P. pastoris expression vector pPICZα as previously described (47).

The following synthetic oligonucleotide primers were used in the PCR: 5’-TCTCTCGAGAAAAAGAGGCAGCCCCCTGGGG-
A Novel Role of Collagen Glycosylation

ACGCGC-3’ (for amplification of both D1–3 and D1–4), 5’-GCTCTAGATTTAATGATGATGATGATGGGCGT-
TGGGCTTCTTCTTGC-3’ (for D1–3), and 5’-GCTCTAGA-
TATTATGATGATGATGACGGCTGCCGCTTCTTGC-3’ (for D1–4). Restriction enzyme recognition sites are in bold. The DNA encoding the specified sequences were inserted at a position leading to N-terminal fusion with a P. pastoris signal sequence to allow protein export into the growth medium and processing mediated by the host cell. The recombinant proteins were purified from filtered supernatant from overnight P. pastoris cultures using Ni²⁺-chelating chromatography on an ÄKTA purifier system (GE Healthcare) and elution with a linear imidazole gradient ranging from 0.005 to 1 M. Homogenous protein preparations were obtained by enzymatic deglycosylation, treating the elution fractions (protein concentration 0.1–0.5 mg/ml) with EndoH (200 units/ml) in 50 mM sodium citrate buffer, pH 5.5, for 1 h at room temperature. A second round of Ni²⁺-chelating chromatography was then performed to remove EndoH enzyme. The D1–10 recombinant uPARAP protein construct was fused to a purification tag (the third domain of the urokinase receptor), produced in Drosophila Schneider S2 cells, and purified by affinity chromatography as previously described (37, 48).

**Gel Electrophoresis Analysis of Recombinant uPARAP**—SDS-PAGE analysis of purified D1–3 and D1–4 was performed under reducing conditions with ~3 μg of protein loaded onto the gel. SDS-PAGE analysis of D1–10 was performed under nonreducing conditions and 5 μg of this protein was loaded. Following SDS-PAGE proteins were stained with Coomassie Brilliant Blue.

**Surface Plasmon Resonance Analysis**—Dynamic analysis of collagen-uPARAP interactions was performed using a Biacore2000 instrument (GE Healthcare), using conditions slightly modified from the method previously described (37). The anti-uPARAP catching antibody (mAb 2h9) was coupled to the surface of a Biacore CM5 sensor chip, after which D1–3 and D1–4 recombinant proteins were immobilized by injection into individual flow channels. Due to the binding characteristics of mAb 2h9, this leads to a near irreversible immobilization of the uPARAP proteins (37). To allow comparison, approximately equal molar amounts of D1–4 and D1–3 were immobilized by this procedure (molar ratios D1–4/D1–3 of 1.087 and 1.118 for the experiments shown in Fig. 2, A and C and Fig. 2, B and D, respectively). Collagens type I and IV were preincubated in assay buffer (10 mM HEPES, 150 mM NaCl, 1 mM CaCl₂, 0.005% surfactant P20, pH 7.4) and were then injected into the flow cell with immobilized uPARAP variants at a flow rate of 10 μl/min for 10 min. In experiments with denatured collagen, collagen I was incubated at 65 °C for 20 min prior to injection. Following injection, dissociation was recorded in two phases: an initial 4-min phase performed in assay buffer alone followed by a 10-min phase performed in assay buffer supplemented with interaction inhibitors (EDTA (10 mM) or GlcNAc (50 mM)). Binding and dissociation were recorded at 20 °C. After each round of collagen injection and dissociation, the chip was regenerated by two pulses of 1 min each with 10 mM glycine/HCl, pH 2.0. A reference flow channel without coupled protein or with mAb 2h9 alone (no recombinant uPARAP) allowed for buffer bulk subtraction throughout each sensorgram. No binding of collagen was observed in the reference channels.

**ELISA Interaction Analysis**—The interaction of uPARAP with immobilized collagens was analyzed using an ELISA setup with heat-denatured collagens type I, IV, and V. Collagens were diluted to 10 μg/ml in coating buffer (0.1 M Na₂CO₃, pH 9.8) and incubated for 20 min at 65 °C before being coated onto the surface of wells in 96-well Nunc Maxisorp plates (Thermo Fisher Scientific, Waltham, MA) at 4 °C overnight. Subsequently, blocking of nonspecific binding sites was performed with either 2.5% ELISA blocking reagent (Roche Diagnostics, used for D1–3 and D1–4 experiments) or 2% skimmed milk powder (Irma, Copenhagen, Denmark, used for D1–10) for 30 min at room temperature. Solutions of 27 nM D1–3 or D1–4, or 55 nM D1–10 were then added to the wells in binding buffer (50 mM HEPES, 20 mM KCl, 100 mM NaCl, 10 mg/ml of BSA, 0.1% Tween 20, pH 7.4), either supplemented with CaCl₂ (1 mM), or with interaction inhibitors (EDTA (3 mM) or mannose (50 mM)). Ligand binding was performed at 4 °C overnight. Binding was detected with primary mouse anti-uPARAP antibody (mAb 2h9, 10 μg/ml) followed by horseradish peroxidase (HRP)-coupled rabbit anti-mouse antibody ((Dako, Glostrup, Denmark) diluted 1:2000) and finally ~20 min incubation with HRP substrate (0.0025% H₂O₂, and 0.33 mg/ml of o-phenylenediamine) (Dako). The reaction was stopped by addition of 1.3 M H₂SO₄ after which the reaction product was quantified by absorbance measurements at 490 nm with absorbance at 540 nm used for background subtraction. In between each incubation step, ELISA plates were washed three times in PBS with 1.7 mM Mg²⁺, 1.3 mM Ca²⁺, and 0.1% Tween 20. After the incubation step with secondary antibody three additional washes were performed with Milli-Q water.

**Treatment of Collagens with Trifluoromethanesulfonic Acid (TFMS)**—For deglycosylation studies, collagens type I, IV, and V were treated with TFMS (49), using a commercial protein deglycosylation kit (Sigma). TFMS treatment was performed according to the manufacturer’s instructions and 200 μg of each collagen was treated. Immediately after treatment, collagens were diluted to 10 μg/ml in ELISA coating buffer (0.1 M Na₂CO₃, pH 9.8). In the mock treated samples, collagens were lyophilized and then redissolved in 10 mM acetic acid before being diluted to 10 μg/ml in ELISA coating buffer.

**Endocytosis Assays**—Internalization assays with ¹²⁵I-labeled ligands in mouse skin fibroblasts isolated from newborn uPARAP-deficient or wild type mice and MG63 cells were performed as previously described (29). In brief, samples of 1 × 10⁵ cells were seeded in 24-well tissue culture plates and cultured overnight. In experiments with function-blocking antibody (mAb 5f4 against uPARAP), 10 μg/ml of the antibody was added to MG63 cells 5 h after seeding. The next day, culture medium was removed and cells were washed with serum-free assay buffer (low glucose DMEM with sodium pyruvate for fibroblasts and minimum Eagle’s medium for MG63 cells; both from Invitrogen) supplemented with 20 mM HEPES and 15 mg/ml of BSA. Subsequently, fresh assay medium was added, with the inclusion of either no inhibitor, 50 mM mannose, 50 mM GlcNAc, 50 mM a-Me-Gal, or 10 μg/ml of mAb 5f4. In addition, the cysteine protease inhibitor E64d (10 μM) was...
added to all samples to optimize lysosomal accumulation of internalized proteins (32). After a 30-min incubation, 133 ng/ml of $^{125}$I-labeled ligand (collagens type I, IV, V, holotransferrin, or anti-uPARAP mAb 2h9) was added to each well. Cultures were then incubated for 4–5 h at 37 °C before the intracellular fraction was isolated as described (29).

For endocytosis assays with human macrophages, $2 \times 10^5$ cells were seeded in each well of a 24-well tissue culture plate and assayed on day 8 according to the isolation and differentiation procedure described above. Internalization assays with $^{125}$I-labeled ligands were performed essentially as described for fibroblasts and MG63 cells. In experiments including mAb 5f4, 10 μg/ml of the antibody was added to the macrophage cultures on day 7. On day 8 assay buffer (AIM-V supplemented with 20 mM HEPES and 15 mg/ml of BSA, 10 μM E64d) was added to the wells with the inclusion of either no inhibitor, 50 mM mannose, 10 μg/ml of pAb a-MR, or 10 μg/ml of mAb 5f4.

Internalization assays with fluorescent collagen or gelatin were performed essentially as described (32). In brief, samples of $2 \times 10^5$ uPARAP-deficient or wild type fibroblasts were seeded overnight, after which ligands for internalization (25 μg/ml of Oregon Green-gelatin or 10 μg/ml of Alexa 488-labeled collagen IV) were added in assay buffer (low glucose DMEM with sodium pyruvate, supplemented with 20 mM HEPES 15 mg/ml of BSA, 1% penicillin/streptomycin, and 10 μM E64d). Internalization was then allowed to proceed overnight in the presence or absence of 50 mM mannose. Following internalization, cells were treated with trypsin-EDTA for 5 min and re-seeded on polylysine-coated coverslips. Cells were allowed to attach for 4 h before being fixed with 4% paraformaldehyde and surface stained with anti-uPAR antibody (10 μg/ml) and secondary Cy3-conjugated goat anti-mouse antibody (diluted 1:200) (Jackson ImmunoResearch). Cell nuclei were stained with DAPI. Fluorescence microscopy was performed as previously described (32), except that a Zeiss LSM 780 microscope was used.

RESULTS

Recombinant uPARAP Variants—To address a possible function of the calcium-dependent lectin domain, CTLD-2, in the uPARAP-collagen interaction we designed two recombinant uPARAP proteins. Both recombinant proteins comprised the first three domains in the uPARAP sequence and in addition one of them contained the fourth domain, CTLD-2. These recombinant proteins were designated D1–3 and D1–4, respectively (Fig. 1A). These recombinant proteins were expressed in P. pastoris and both were purified to yield homogeneous products (Fig. 1B, left panel). By comparing D1–3 and D1–4 constructs with respect to the binding of various collagen subtypes, the importance of CTLD-2 could be directly assessed.

Differential Binding of uPARAP to Different Collagen Subtypes—The interactions between collagens and the D1–3 and D1–4 constructs were initially analyzed by surface plasmon resonance (SPR) using an established setup where recombinant uPARAP is immobilized on a supporting, high affinity monoclonal antibody (mAb 2h9) (37). Because this setup includes a divalent capture of the receptor on a catching IgG, it precludes the derivation of quantitative kinetic parameters of monomeric uPARAP. However, it does enable the qualitative analysis of separate collagen association and dissociation phases.

First, we studied the interaction between the recombinant uPARAP constructs and collagen IV, a collagen with a high degree of glycosylation (9). When injected in a calcium-containing running buffer, collagen IV clearly bound more rapidly to D1–4 than to the equivalent molar amount of D1–3 (Fig. 2A). To study whether this difference in binding was dependent on calcium, the collagen injection pulse was followed by a short dissociation phase, after which an EDTA-containing buffer was injected. Strikingly, the chelation of calcium strongly affected the dissociation of collagen IV from D1–4 and brought the binding signal to a level similar to that obtained with D1–3. The binding between collagen IV and D1–3 itself was unaffected by EDTA.

Next, we analyzed the interaction between the recombinant uPARAP proteins and collagen I, a collagen with a low degree of glycosylation (13). This ligand bound with similar efficiency to...
D1–4 and D1–3, leading to nearly identical association and dissociation phases, and EDTA did not appear to affect the dissociation of collagen I from either construct (Fig. 2B, lower curves). However, although the complexes formed between collagen I and the uPARAP constructs were highly stable as indicated by the low dissociation rate, the slow binding process with this ligand led to relatively low binding levels under the conditions used. Therefore, it was difficult to rule out the possibility that EDTA could have a small effect on the stability of the complexes formed with collagen I. To exclude this, an additional experiment was set up in which collagen I was denatured prior to injection. We have previously shown that collagen cleaved by specific collagenases binds more rapidly to uPARAP than native collagen and that collagen cleavage can be mimicked in this respect by heat-induced denaturation while retaining binding specificity (37). Indeed, denaturation of collagen I resulted in a faster association reaction and, consequently, a higher binding level than that obtained with native collagen I, allowing for a detailed evaluation of the dissociation curves (Fig. 2B, upper curves). Also under these conditions, EDTA was clearly without effect on the dissociation of collagen I from D1–4 and D1–3.

The Active Lectin Domain of uPARAP Participates in the Collagen Interaction—To further investigate if the observed calcium-dependent effects were related to the lectin activity of CTLD-2, the effect of monosaccharide on collagen interaction was analyzed using the same SPR setup. The injection of GlcNAc, which has previously been identified as a ligand for CTLD-2 (41), efficiently accelerated the dissociation of collagen IV from D1–4 (Fig. 2C), although the effect obtained was slightly weaker than that found with EDTA. The binding between collagen IV and D1–3 was unaffected by GlcNAc injection. Furthermore, GlcNAc did not affect the interaction between native or denatured collagen I and D1–4 or D1–3 (Fig. 2D). A similar result as obtained here with GlcNAc could also be obtained with mannose, another positive monosaccharide ligand for CTLD-2 (41) (result not shown). The effect of α-Me-Gal, a monosaccharide found to be a very poor ligand for CTLD-2 (41), was also analyzed. This monosaccharide did not influence the interaction between collagen IV and D1–4 or D1–3 (result not shown, but see Fig. 3, below). Together these experiments suggested a role of the lectin activity of CTLD-2 in the interaction between uPARAP and collagen IV and a lack of importance of this domain in the interaction with collagen I.
To examine this mechanism in an independent system, an ELISA setup was developed that allowed us to study binding between recombinant uPARAP in solution and collagens immobilized in microtiter wells. Initial experiments revealed that in this setup, uPARAP binding levels well suited for quantitative analysis could be obtained with immobilized denatured collagens, whereas the signals obtained with native collagens were too low for a detailed comparison of binding conditions. Consequently, denatured collagens with high and low levels of glycosylation were coated onto the ELISA well surface, after which D1–4 or D1–3 were added in solution. In the presence of calcium, D1–4 bound much more efficiently to collagen IV than to collagen I (Fig. 3A). Calcium chelation by EDTA or competition with mannose efficiently reduced the binding of D1–4 to collagen IV, whereas α-Me-Gal had no effect. The binding of D1–4 to collagen I was unaffected by EDTA, mannose, or α-Me-Gal. Importantly, these differences were not observed in the case of D1–3 (Fig. 3B). D1–3 bound with similar efficiency to collagen IV and I, and neither EDTA, mannose, nor α-Me-Gal had an effect on the binding. Thus, the ELISA experiments were in accordance with the SPR analyses and confirmed that CTLD-2 is engaged in the interaction of uPARAP with collagen IV and that it contributes to the binding through its calcium-dependent lectin activity.

To exclude that the observed effects were caused by artifacts related to the expression of short truncated recombinant proteins in a P. pastoris-based expression system, a previously characterized recombinant protein, D1–10, was included in the study. This purified protein includes all of the extracellular domains of uPARAP and was expressed in insect cells (37) (Fig. 1, A and B, right panels). In the ELISA setup the binding of D1–10 to collagen IV was sensitive to calcium chelation by EDTA and competition by mannose, whereas α-Me-Gal only had very limited effect. The binding to collagen I was not inhibited by any of the tested reagents (Fig. 3C). Therefore, D1–10 showed binding characteristics toward collagen IV and I very similar to those observed for D1–4.

**The Active Lectin Domain of uPARAP Interacts Directly with Carbohydrates on Collagen**—A likely hypothesis to explain the results above was that CTLD-2 strengthens the receptor-collagen binding by interacting directly with carbohydrates on collagen.

To test this hypothesis, collagen IV and I were treated with TFMS to remove covalently attached carbohydrates (49). Following TFMS treatment, interaction between the deglycosylated collagens and D1–4, D1–3, or D1–10 was compared in the same ELISA system as used above (Fig. 4). In the presence of calcium, D1–4 bound much more efficiently to collagen IV than to collagen I (Fig. 3A). Calcium chelation by EDTA or competition with mannose efficiently reduced the binding of D1–4 to collagen IV, whereas α-Me-Gal had no effect. The binding of D1–4 to collagen I was unaffected by EDTA, mannose, or α-Me-Gal. Importantly, these differences were not observed in the case of D1–3 (Fig. 3B). D1–3 bound with similar efficiency to collagen IV and I, and neither EDTA, mannose, nor α-Me-Gal had an effect on the binding. Thus, the ELISA experiments were in accordance with the SPR analyses and confirmed that CTLD-2 is engaged in the interaction of uPARAP with collagen IV and that it contributes to the binding through its calcium-dependent lectin activity.

To exclude that the observed effects were caused by artifacts related to the expression of short truncated recombinant proteins in a P. pastoris-based expression system, a previously characterized recombinant protein, D1–10, was included in the study. This purified protein includes all of the extracellular domains of uPARAP and was expressed in insect cells (37) (Fig. 1, A and B, right panels). In the ELISA setup the binding of D1–10 to collagen IV was sensitive to calcium chelation by EDTA and competition by mannose, whereas α-Me-Gal only had very limited effect. The binding to collagen I was not inhibited by any of the tested reagents (Fig. 3C). Therefore, D1–10 showed binding characteristics toward collagen IV and I very similar to those observed for D1–4.

### Figure 3: ELISA analysis of uPARAP interactions with immobilized collagens.

Heat-denatured collagen types IV and I were immobilized in ELISA wells as indicated below each panel. D1–4 (27 nM, A), D1–3 (27 nM, B), or D1–10 (55 nM, C) was added to each well. The binding was analyzed in assay buffer with 1 mM CaCl_2 and no further additions (gray columns), buffer with 3 mM EDTA (hatched gray columns), buffer with 1 mM CaCl_2 and 50 mM mannose (white columns), and buffer with 1 mM CaCl_2 and 50 mM α-Me-Gal (hatched white columns). Binding of the recombinant uPARAP proteins was detected with mAb 2h9 against uPARAP, followed by a secondary HRP-coupled rabbit anti-mouse antibody. Controls comprised wells without immobilized collagen (coating control, black columns) and wells without recombinant uPARAP (negative in all cases). Error bars represent S.D. of duplicate samples.
calcium, the binding of D1–4 to TFMS-treated collagen IV proved strongly reduced as compared with the binding to the same type of collagen after mock treatment (Fig. 4A). In fact, in the absence of inhibitors, this binding was nearly reduced to the same level as that obtained with mock treated collagen IV in the presence of EDTA. Furthermore, after TFMS treatment of col-
A Novel Role of Collagen Glycosylation

The Lectin Function of uPARAP Is Active in the Cellular Uptake of Glycosylated Collagen—The results presented above were so far limited to a system with purified proteins. Therefore, we wanted to investigate if the binding contribution of CTLD-2 is directed to the carbohydrates on glycosylated collagens.

First, we examined the uptake of holotransferrin, a ligand endocy- tosized through a clathrin-dependent mechanism similar to the collagen-uPARAP system, but mediated by the transferrin receptor (50). When 125I-labeled holotransferrin was added to the same cell types as used above, no effect of the monosaccharides was noted (Fig. 5, E and F), demonstrating that these reagents had no general effect on clathrin-dependent endocy- tosis. Second, to address any effect of the monosaccharides spe- cifically against the cellular endocytosis of uPARAP, we exploited the fact that uPARAP is capable of internalizing mAbs directed against it (51). When mAb 2h9 against uPARAP was labeled with 125I and added to uPARAP+/- fibroblasts or MG63 cells, none of the monosaccharides had any effect on internalization (Fig. 5, G and H). In uPARAP+/− fibroblasts and MG63 cells treated with the blocking mAb 5f4, the internaliza- tion of mAb 2h9 was very low, documenting that the endocytosis was uPARAP dependent. Therefore, carbohydrate sensitivity of the internalization experiments above was indeed limited to the uPARAP-mediated uptake of glycosylated collagens.

Finally, to directly visualize the uPARAP-dependent uptake and the lysosomal accumulation of collagens, we employed an experimental setup with fluorescently labeled collagens, which allows the demonstration of the internalized ligand in endo- somes and lysosomes by fluorescence microscopy (32, 37). Fluorescence-labeled collagen IV and gelatin (denatured collagen I) were added to uPARAP+/- fibroblasts in the absence or pres- ence of mannose. When fluorescence-labeled collagen IV was used, a strong reduction in the vesicular accumulation of fluo- rescence was detected in the presence of mannose, compared with cells where no competitor was added (Fig. 6A, upper and center panels). In contrast, no effect of mannose was observed in the case of the gelatin ligand (Fig. 6B, upper and center pan- eels). uPARAP−/- fibroblasts were used as a specificity control and as expected failed to accumulate intracellular collagen IV as well as gelatin (Fig. 6, A and B, lower panels). Altogether, these experiments were in complete accordance with results from the protein-protein interaction analyses and demonstrated a spe- cific inhibitory effect of CTLD-2 monosaccharide ligands on the uPARAP-mediated endocytosis and lysosomal routing of highly glycosylated collagens.

Mannose Receptor-mediated Collagen Uptake Is Independent of Lectin Activity—The demonstration of an active lectin domain being important for uPARAP binding and internaliza- tion of the glycosylated collagens opened the possibility that a similar mechanism could be employed by the MR. This recep- tor is another collagen binding member of the same protein family, having the same domain composition as uPARAP (23) and has been shown to be active in collagen internalization in macrophages (42, 43).
A Novel Role of Collagen Glycosylation

Fibroblasts

Collagen IV

A) Internalized ligand (% of added material)

| uPARAP +/+ | uPARAP -/- |
|------------|------------|
|            |            |
|            |            |
|            |            |
|            |            |

MG63

Collagen IV

B) Internalized ligand (% of added material)

| uPARAP +/+ | uPARAP -/- |
|------------|------------|
|            |            |
|            |            |
|            |            |
|            |            |

Collagen I

C) Internalized ligand (% of added material)

| uPARAP +/+ | uPARAP -/- |
|------------|------------|
|            |            |
|            |            |
|            |            |
|            |            |

D) Internalized ligand (% of added material)

| uPARAP +/+ | uPARAP -/- |
|------------|------------|
|            |            |
|            |            |
|            |            |
|            |            |

Holo-transferrin

E) Internalized ligand (% of added material)

| uPARAP +/+ |
|------------|
|            |
|            |
|            |
|            |

F) Internalized ligand (% of added material)

| uPARAP +/+ |
|------------|
|            |
|            |
|            |
|            |

mAb 2h9

G) Internalized ligand (% of added material)

| uPARAP +/+ | uPARAP -/- |
|------------|------------|
|            |            |
|            |            |
|            |            |
|            |            |

H) Internalized ligand (% of added material)

| uPARAP +/+ | uPARAP -/- |
|------------|------------|
|            |            |
|            |            |
|            |            |
|            |            |

Legend:
- No competitor
- mannose
- GlcNAc
- α-me-gal
- uPARAP -/-, no competitor
- anti-uPARAP mAb 5f4
To study the cellular collagen uptake through MR, 125I-labeled collagen IV and I were added to human macrophages. For both ligands, in accordance with studies published previously (43), this uptake process was governed by MR because a polyclonal antibody against this receptor (a-MR pAb) efficiently blocked the internalization of both collagens (Fig. 7, A and B). Strikingly, however, mannose did not have any effect on the internalization of either collagen IV or I in these cells. In contrast, both mannose and the a-MR pAb strongly inhibited the ability of the macrophage to internalize mannose-BSA (Fig. 7C), a well established ligand for the active CTLDs of MR (52), thus documenting that mannose is indeed a competitor of CTLD-dependent internalization of MR-ligands.

In a control experiment, neither mannose nor the a-MR pAb had any effect on the internalization of holotransferrin by macrophages (Fig. 7D) and furthermore, the a-MR pAb did not reduce the uPARAP-dependent internalization of collagens in MG63 cells (supplemental Fig. S3). Altogether, the cell-based experiments demonstrate an MR-dependent, but lectin-independent, internalization of glycosylated collagens by cultured macrophages and point to a clear difference in lectin functions between uPARAP and MR.

**DISCUSSION**

In this study, we have examined the importance of collagen glycosylation for interaction with the collagen endocytosis receptor uPARAP. We showed that CTLD-2, the single active lectin domain of uPARAP (41), contributes strongly to the interaction between uPARAP and glycosylated collagens. Competition experiments with monosaccharides and collagen deglycosylation studies pointed to this being the result of a direct binding between CTLD-2 and protein carbohydrate on collagen ligands. We first demonstrated in two independent purified systems that CTLD-2 strengthens the interaction between uPARAP and glycosylated collagens. Competition experiments with monosaccharides and collagen deglycosylation studies pointed to this being the result of a direct binding between CTLD-2 and protein carbohydrate on collagen ligands. We first demonstrated in two independent purified systems that CTLD-2 strengthens the interaction between uPARAP and glycosylated collagens in a calcium- and carbohydrate-dependent manner and that this contribution could be blocked by monosaccharide ligands of CTLD-2. Second, we showed that the uptake and lysosomal routing of these collagens by mouse skin fibroblasts and human osteosarcoma cells is increased because of this binding contribution. To our knowledge this is the first time that a specific receptor interaction with biologically occurring collagen glycosylation has been identified and it is the first time that a biological ligand has been identified for CTLD-2 in uPARAP.

Previous studies with recombinant, truncated uPARAP constructs have convincingly shown that the FN-II domain plays a central role in collagen binding (30), but did not identify a role of CTLD-2 in this respect. However, these studies did not focus on differential glycosylation among different types of collagen and the findings were mostly based on a positive collagen binding capability of a recombinant protein comprising just the first three domains of uPARAP. This is in complete accordance with our findings that the D1–3 construct binds to collagens and does so independently of carbohydrate. Relative to this binding, we found an increased binding of the D1–4 construct exclusively to glycosylated collagens. In this connection, it is noteworthy that the three-domain construct in the previous work was also found to bind less efficiently to collagen IV than a longer construct (30), although the background for this finding was not identified.

Whereas our findings thus show that CTLD-2 contributes to the binding of glycosylated collagens through its lectin activity, this interaction is clearly not responsible for binding alone. Although both monosaccharides and EDTA inhibition led to a pronounced reduction in binding, neither of these reagents abolished binding completely. In line with these observations, previous studies have demonstrated that CTLD-2 is not sufficient for collagen binding in the absence of the N-terminal part of the receptor because a truncated uPARAP variant, including CTLD2–8 but lacking the FN-II domain, is unable to bind collagen IV (31).

The relative positioning of the FN-II domains and the active lectin domains differs within the MR protein family (see Ref. 23). This may be important for the lectin contribution to collagen binding because we found that in contrast to uPARAP, MR does not depend on lectin activity in the uptake of collagens. This is noteworthy because MR includes active lectin domains (52) with several known carbohydrate ligands (for a review, see Ref. 23) but it does support previously published results on the MR-collagen interaction in a purified system, which suggest that MR binds collagen IV independently of the lectin activity (42, 53). Therefore, strong evidence now supports distinct functions of lectin domains found in the closely related receptors uPARAP and MR.

Although the molecular details of the collagen carbohydrate that binds to uPARAP are not known, it is quite likely that the interaction involves the unique type of collagen O-glycosylation (7). This type of glycosylation is elevated in collagen types IV and V, found in this study to be CTLD-2 ligands. versus the non-ligand collagen I. Furthermore, it includes terminal glucose residues (7), in accordance with glucose being an established monosaccharide ligand of CTLD-2 (41). Finally, this type of glycosylation is scattered across the helical regions of the collagen α-chains and therefore is positioned close to regions containing the presumed binding sites for the FN-II domain of uPARAP (37, 54).

The demonstration of an interaction between collagen carbohydrate and CTLD-2 opens new questions concerning the function of collagen glycosylation as well as uPARAP. The importance of collagen post-translational modifications is well recognized and mutations in responsible genes have been implicated in various diseases in both mice and humans (55). However, the role of collagen glycosylation is generally not well

**FIGURE 5. Carbohydrate dependence of uPARAP-mediated collagen endocytosis.** 125I-Labeled collagens types IV (A and B) or I (C and D), holotransferrin (E and F), or mAb 2H9 (G and H) were added to uPARAP+ and uPARAP− fibroblasts, as indicated (A, C, E, and G). In a parallel experiment, the same ligands were added to MG63 cells (B, D, F, and H). The labeled proteins (133 ng/ml) were added in endocytosis assay buffer alone (no competitor), in buffer including 50 mM of the indicated monosaccharides, or in buffer including 10 μg/ml of mAb 5F4. After 4 h at 37 °C the cells were harvested, the intracellular fraction of cell samples was isolated, and the amount of internalized labeled protein was determined. Data are presented as radioactivity in the intracellular fraction of cells, relative to the total amount of radioactivity added. Error bars represent the S.D. of triplicate samples.
defined in molecular terms, although the importance of collagen O-glycosylation has recently become more apparent. In mice it has been demonstrated that O-glycosylation is essential for the proper structural assembly of collagens, especially collagen IV, and that genetic deletion of the enzyme catalyzing this glycosylation process leads to incomplete formation of basement membranes and, as a consequence, to embryonic lethality (14–16). In humans, mutations in the corresponding gene, which result in decreased collagen glycosylation activity, have now been shown to cause severe connective tissue disorders resembling disorders caused by mutations in collagen-encoding genes (56, 57). The structural importance of collagen O-glycosylation is further demonstrated by the finding that increased levels of O-glycosylation decrease the diameter of fibers formed by fibrillar collagens II and V in vitro (58, 59), and it has been suggested that an increase in collagen I glycosylation in vivo can

**FIGURE 6.** Influence of carbohydrate on lysosomal collagen accumulation. uPARAP⁺/⁺ and uPARAP⁻/⁻ fibroblasts were incubated with Alexa 488-labeled collagen IV (A) or Oregon Green-labeled gelatin (B) in the absence (no competitor) or presence of 50 mM mannose. Endocytosis was allowed to proceed during incubation overnight. Subsequently, cells were released, re-seeded on coverslips, fixed, and stained with a cell surface marker (anti-uPAR antibody followed by Cy3-conjugated secondary antibody; red fluorescence). Cell nuclei were stained with DAPI (blue). Cells were then examined by confocal microscopy. The left panels show the channel with green fluorescence alone (fluorescent collagen IV/gelatin), whereas the right panels show the merged images with green, red, and blue fluorescence. Note the vesicular accumulation of internalized collagen/gelatin.

**FIGURE 7.** Collagen internalization in macrophages. Cultured macrophages were incubated with ¹²⁵I-labeled collagens type IV (A) or type I (B), mannose-BSA (C), or holotransferrin (D). Incubation was performed in the absence (no competitor) or presence of the following reagents: mannose (50 mM), a-MR pAb (10 μg/ml), or mAb 5f4 against uPARAP (5f4; 10 μg/ml). Following incubation for 4 h at 37°C, the internalized fraction of labeled protein was determined. Data are presented as described in the legend to Fig. 5.
lead to the altered collagen architecture seen in sclerotic skin (60).

Together, these studies suggest that collagen glycosylation must be tightly regulated to ensure proper deposition and structuring of ECM compartments, including the basement membrane. In addition to this function, our findings now suggest a role of collagen glycosylation in matrix turnover through the link to uPARAP-mediated endocytosis, with collagen carbohydrates modulating turnover efficiency.

uPARAP has been found to be important for numerous processes involving degradation of the major types of collagen, notably including both fibrillar and network-forming collagens. In vivo, uPARAP-dependent collagen turnover has been shown to be central in the development of bone in cattle (39) and mice (25, 36), a tissue rich in fibrillar collagen. In ECM turnover in breast cancer and gliomas (61–63), uPARAP is likely to be important for the degradation of both fibrillar and network forming collagens. Particularly, in mouse mammary cancer a pronounced accumulation of collagen I and collagen IV has been demonstrated inside tumors as a result of uPARAP deficiency (61). Furthermore, the receptor has been found to be expressed in the stroma of several types of cancer in humans (44, 64–66) as well as in wound healing (27).

In vitro, the importance of uPARAP-mediated endocytosis of glycosylated collagen has been underscored by experiments demonstrating that the invasiveness of glioma cell lines in collagen IV-rich matrices is almost completely suppressed by RNAi depletion of uPARAP (66), and by experiments demonstrating that uPARAP mediates endocytosis of collagen IV by stromal cells of mammary tumors explanted from mice (61). Together, these experiments point to a regulatory role of the newly discovered uPARAP lectin function in invasive processes.

The demonstration of an interplay between collagen carbohydrates and uPARAP-mediated endocytosis opens the possibility that uPARAP plays a role in other physiological and pathological processes. Thus, some of the deleterious effects resulting from changes in collagen glycosylation may include an altered cellular uptake through uPARAP and, as a result, an imbalance in collagen turnover.

In rheumatoid arthritis, which involves excessive degradation of ECM in joint cartilage and bone, elevated levels of carbohydrate derivatives on collagen degradation products in the urine of patients have been correlated with tissue destruction (67, 68). Indeed, in mice uPARAP has been found to be expressed by chondrocytes in cartilage during development (26, 36) and it is an intriguing hypothesis that uPARAP may participate in the excessive collagen degradation observed in patients with rheumatoid arthritis. This increase could be influenced by elevated levels of collagen glycosylation.

In diabetes, alterations in extracellular matrices connected with the microvasculature are crucially involved in severe complications of the disease. Diabetes is accompanied by elevated concentrations of glucose in tissues and thickening of basement membranes, particularly in the microvascular system (69, 70). Our results indicate that the interaction between uPARAP and collagen IV is sensitive to high carbohydrate concentrations, suggesting that strongly hyperglycemic conditions could affect the local turnover rate of this basement membrane component. Furthermore, diabetes is characterized by the increased non-enzymatic addition of carbohydrates (glycation) to collagens in the ECM. Collagen glycation includes the addition of glucose to hydroxylsine residues (71), creating structures resembling normal collagen O-glycosylation. These changes in collagen carbohydrate content result in deleterious changes in the functional properties of collagen that may include an altered collagen turnover mediated by uPARAP.

Altogether, our present work on the lectin activity of uPARAP points to a function of collagen glycosylation in the cellular uptake process. This provides a novel regulatory level in the dynamic balance between collagen deposition and turnover with several implications in healthy and pathological processes.

Acknowledgments—The excellent technical assistance of Suzanne K. Moller and Katharina H. Stegmann is gratefully acknowledged. We thank the CFIM (Department of Biomedical Sciences, Copenhagen University) for microscope assistance.

REFERENCES
1. Marastoni, S., Ligresti, G., Lorenzoni, E., Colombatti, A., and Mongiat, M. (2008) Connect. Tissue Res. 49, 203–206
2. Rowe, R. G., and Weiss, S. J. (2008) Trends Cell Biol. 18, 560–574
3. Holmbeck, K., and Szabova, L. (2006) Birth Defects Res. C Embryo. Today 78, 11–23
4. Khoshnoodi, J., Cartailler, J. P., Alvares, K., Veis, A., and Hudson, B. G. (2006) J. Biol. Chem. 281, 38117–38121
5. Prockop, D. J., and Kivirikko, K. I. (1995) Annu. Rev. Biochem. 64, 403–434
6. Gelse, K., Pöschl, E., and Aigner, T. (2003) Adv. Drug Deliv. Rev. 55, 1531–1546
7. Sprio, R. G. (1967) J. Biol. Chem. 242, 4813–4823
8. Kresina, T. F., and Miller, E. J. (1979) Biochemistry 18, 3089–3097
9. Sage, H., Woodbury, R. G., and Bornstein, P. (1979) J. Biol. Chem. 254, 9893–9900
10. Sage, H., and Bornstein, P. (1979) Biochemistry 18, 3815–3822
11. Hong, B. S., Davison, P. F., and Cannon, D. J. (1979) Biochemistry 18, 4278–4282
12. Aguilar, J. H., Jacobs, H. G., Butler, W. T., and Cunningham, L. W. (1973) J. Biol. Chem. 248, 5106–5113
13. Sprio, R. G. (1969) J. Biol. Chem. 244, 602–612
14. Rautavuoma, K., Takaluoma, K., Sormunen, R., Myllyharju, J., Kivirikko, K. I., and Soininen, R. (2004) Proc. Natl. Acad. Sci. U.S.A. 101, 14120–14125
15. Ruotsalainen, H., Siplälä, L., Vapola, M., Sormunen, R., Salo, A. M., Utito, L., Mercer, D. K., Robins, S. P., Risteli, M., Aszodi, A., Fassler, R., and Myllylä, R. (2006) J. Cell Biol. 119, 625–635
16. Siplälä, L., Ruotsalainen, H., Sormunen, R., Baker, N. L., Lamandé, S. R., Vapola, M., Wang, C., Sado, Y., Aszodi, A., and Myllylä, R. (2007) J. Biol. Chem. 282, 33381–33388
17. Lauer-Fields, K. J., Luxja, D., and Fields, G. B. (2002) Biopolymers 66, 19–32
18. Song, F., Wisithprom, K., Zhou, J., and Windsor, L. J. (2006) Front. Biosci. 11, 3100–3120
19. Mohamed, M. M., and Sloane, B. F. (2006) Nat. Rev. Cancer 6, 764–775
20. Behrendt, N. (2004) Biol. Chem. 385, 103–136
21. Sheikh, H., Yarwood, H., Ashworth, A., and Isacke, C. M. (2000) J. Cell Sci. 113, 1021–1032
22. Wu, K., Yuan, J., and Lasky, L. A. (1996) J. Biol. Chem. 271, 21323–21330
23. East, L., and Isacke, C. M. (2002) Biochim. Biophys. Acta 1572, 364–386
24. Engelholm, L. H., Ingvarsen, S., Jürgensen, H. I., Hillig, T., Madsen, D. H., Nielsen, B. S., and Behrendt, N. (2009) Front. Biosci. 14, 2103–2114
25. Engelholm, L. H., Nielsen, B. S., Netzel-Arnett, S., Solberg, H., Chen, X. D., Lopez Garcia, J. M., Lopez-Otin, C., Young, M. F., Birkedal-Hansen, H.,...
A Novel Role of Collagen Glycosylation

Dano, K., Lund, L. R., Behrendt, N., and Bugge, T. H. (2001) Lab. Invest. 81, 1403–1414

26. Howard, M. J., Chambers, M. G., Mason, R. M., and Isacke, C. M. (2004) Osteoarthr. Cartil. 12, 74–82

27. Honardoust, H. A., Jiang, G., Koivisto, L., Wienke, D., Isacke, C. M., Larjava, H., and Hääkkilä, L. (2006) Histopathology 49, 634–648

28. Smith, L., Wagner, T. E., Huizar, I., and Schnapp, L. M. (2008) Gene Expr. Patterns 8, 486–493

29. Engelholm, L. H., List, K., Netzelt-Arnett, S., Cukierman, E., Mitola, D. J., Aaronson, H., Kjeller, L., Larsen, J. K., Yamada, K. M., Strickland, D. K., Holmbeck, K., Dano, K., Birkedal-Hansen, H., Behrendt, N., and Bugge, T. H. (2003) J. Cell Biol. 160, 1009–1015

30. Wienke, D., MacFadyen, J. R., and Isacke, C. M. (2003) Mol. Biol. Cell 14, 3592–3604

31. East, L., McCarthy, A., Wienke, D., Sturge, J., Ashworth, A., and Isacke, C. M. (2003) EMBO Rep. 4, 310–3116

32. Kjær, M., Gårdsvoll, H., Høyer-Hansen, G., and Lund, L. R., Behrendt, N., and Engelholm, L. H. (2011) J. Cell Biol. 194, 1074–1082

33. Madsen, D. H., Ingvarsen, S., Hillig, T., Wagenaar-Miller, R. A., Kjeller, L., Gårdslov, H., Høy-Hansen, G., Holmbeck, K., Bugge, T. H., and Behrendt, N. (2007) J. Biol. Chem. 282, 27037–27045

34. Messaritou, G., East, L., Rohgi, C., Isacke, C. M., and Yarwood, H. (2009) J. Cell Sci. 122, 4042–4048

35. Asplund, K., Larsson, J., and Isacke, C. M. (2002) J. Biol. Chem. 277, 50469–50475

36. Martinez-Pomares, L., Wienke, D., Stillion, R., McKenzie, E. J., Arnold, J. N., Harris, J., Sim, R. B., Isacke, C. M., and Gordon, S. (2006) Eur. J. Immunol. 36, 1074–1082

37. Madsen, D. H., Ingvarsen, S., Jürgensen, H. J., Melander, M. C., Kjeller, L., Moyer, A., Honoré, C., Madsen, C. A., Garred, P., Burgdorf, S., Bugge, T. H., Behrendt, N., and Engelholm, L. H. (2011) J. Biol. Chem. 286, 26996–27010

38. Sulek, J., Wagenaar-Miller, R. A., Shireman, J., Molinolo, A., Madsen, D. H., Engelholm, L. H., Behrendt, N., and Bugge, T. H. (2007) J. Histoch. Cytochem. 55, 347–353

39. Rasch, M. G., Pass, J., Illlemann, M., Høy-Hansen, G., and Lund, I. K. (2008) J. Immunol. Methods 339, 55–65

40. Honoré, C., Rørvig, S., Munthe-Fog, L., Hummelshøj, T., Madsen, H. O., Borregaard, N., and Garred, P. (2008) Mol. Immunol. 45, 2782–2789

41. Kjaergaard, M., Gårdslov, H., Hirschberg, D., Nielbo, S., Mayaudard, A., Peterson, C. B., Janssen, A., Jørgensen, T. J., Poulsen, F. M., and Ploug, M. (2007) Protein Sci. 16, 1934–1945

42. Gårdslov, H., Hansen, L. V., Jørgensen, T. J., and Ploug, M. (2007) Protein Expr. Purif. 52, 384–394

43. Edge, A. S. (2003) Biochem. J. 376, 339–350

44. Watts, C., and Marsh, M. (1992) J. Cell Sci. 103, 1–8

45. Isacke, C. M., van der Geer, H., Hunter, T., and Trowbridge, I. S. (1990) Mol. Cell. Biol. 10, 2606–2618

46. Taylor, M. E., Beuzeska, K., and Drickamer, K. (1992) J. Biol. Chem. 267, 1719–1726

47. Napper, C. E., Drickamer, K., and Taylor, M. E. (2006) Biochem. J. 395, 579–586

48. Thomas, E. K., Nakamura, M., Wienke, D., Isacke, C. M., Pozzi, A., and Liang, P. (2005) J. Biol. Chem. 280, 22596–22605

49. Myhlyharju, J., and Kivirikko, K. I. (2004) Trends Genet. 20, 33–43

50. Salo, A. M., Cox, H., Farndon, P., Moss, C., Grindulis, H., Risteli, M., Robins, S. P., and Myllylä, R. (2008) Am. J. Hum. Genet. 83, 495–503

51. Risteli, M., Ruotsalainen, H., Salo, A. M., Sormunen, R., Sipilä, L., Baker, N. L., Lamandé, S. R., Vimpuri-Kauptinen, L., and Myllylä, R. (2009) J. Biol. Chem. 284, 28204–28211

52. Notbohm, H., Nokelainen, M., Myllyharju, J., Fietzek, P. P., Müller, P. K., and Kivirikko, K. I. (1999) J. Biol. Chem. 274, 8988–8992

53. Mizuno, K., Adachi, E., Imamura, Y., Katsumata, O., and Hayashi, T. (2001) Microsc. 32, 317–323

54. Brinckmann, J., Notbohm, H., Tronnier, M., Açil, Y., Fietzek, P. P., Schmeller, W., Müller, P. K., and Bäte, B. (1999) J Invest. Dermatol. 113, 617–621

55. Carino, A. C., Engelsbalm, L. H., Yamada, S. S., Holmbeck, K., Lund, L. R., Molinolo, A. A., Behrendt, N., Nielsen, B. S., and Bugge, T. H. (2005) J. Cell. Biol. 169, 977–985

56. Wijnen, D., Davies, G. C., Johnson, D. A., Sturge, J., Lambros, M. B., Savage, K., Elsheikh, S. E., Green, A. R., Ellis, I. O., Robertson, D., Reis-Filho, J. S., and Isacke, C. M. (2007) Cancer Res. 67, 10230–10240

57. Huijbers, I. J., Irvani, M., Popov, S., Robertson, D., Al-Sarraj, S., Jones, C., and Isacke, C. M. (2010) PLoS One 5, e9808

58. Schnack Nielsen, B., Rank, F., Engelsbalm, L. H., Holm, A., Dano, K., and Behrendt, N. (2002) Int. J. Cancer 98, 656–664

59. Kogi, M., Walker, M. M., Waxman, J., and Sturge, J. (2009) Eur. J. Cell. Biol. 85, 685–693

60. Takahashi, S., Yamada-Okabe, H., Hamada, K., Ohta, S., Kawase, T., Yoshida, K., and Toda, M. (2011) J. Neurosci. 103, 267–276

61. Ginets, E., Garnero, P., and Delmas, P. D. (2001) Rheumatology 40, 313–323

62. Garnero, P., Ginets, E., Christgau, S., Finck, B., and Delmas, P. D. (2002) Arthritis Rheum. 46, 21–30

63. Tuilary, E. C. (2003) J. Pathol. 200, 537–546

64. Hayden, M. R., Sowers, J. R., and Tyagi, S. C. (2005) Cardiovasc. Diabetol. 4, 9

65. Avery, N. C., and Bailey, A. J. (2006) Pathol. Biol. 54, 387–395